Well Referenced

Tag: androgenic adverse events

Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial

This randomized, double-blind, placebo-controlled trial evaluated the efficacy of a 300 µg/day testosterone patch in surgically menopausal women with hypoactive sexual desire disorder (HSDD) on estrogen therapy. Over 24 weeks, the testosterone group experienced significant improvements in sexual desire (P < .001), satisfying sexual activity (mean increase of 1.56 episodes

Read More »
June 26, 2025 No Comments

Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder

This randomized, double-blind, placebo-controlled trial evaluated the effects of a 300 µg/day testosterone patch on hypoactive sexual desire disorder (HSDD) in surgically menopausal women receiving estrogen therapy. Over 24 weeks, the testosterone group experienced significant increases in satisfying sexual activity (mean increase of 1.56 episodes per 4 weeks vs. 0.73

Read More »
June 26, 2025 No Comments

Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis

A systematic review and meta-analysis published in Fertility and Sterility (2017) evaluated the efficacy and safety of transdermal testosterone therapy in postmenopausal women with hypoactive sexual desire disorder (HSDD). The study found that transdermal testosterone significantly improved sexual function in both naturally and surgically menopausal women, regardless of concurrent estrogen-progestin

Read More »
June 26, 2025 No Comments